Bayer scores late-stage support for new PAH drug

Just days after nabbing a speedy FDA approval of its cancer drug Stivarga (regorafenib), Bayer says it nailed positive Phase III data on its new drug for rare cases of pulmonary arterial hypertension--and that could set the stage for a three-way market-share battle with Actelion ($ATLN) and Gilead ($GILD) in 2014. Report